source
- J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor programJ&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
- Financing gaps keep $2 million gene therapies out of reach for many patientsWilliam Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…